Moreover, due to the intrinsic characteristics of BRAF mutations, BRAF-driven tumors in humans often exhibit aggressive phenotypes, which correlate with higher engraftment rates and faster tumor growth in vivo—two essential factors for successful PDX generation [19]. The gene discussed is BRAF; the disease is neoplasm.